Medexus Pharmaceuticals (MDP.TO), a specialty pharma company, today announced preliminary revenue estimates for Q4 and the full fiscal year ended March 31st 2023 as well as a business update….
MDP.T
Medexus Pharmaceuticals (MDP.TO), a leading specialty pharma company, today announced that it has secured the Canadian rights to commercialize terbinafine hydrochloride nail lacquer supplied by Polichem, an Almirall group…
10 March 2023
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Chris Parry- MDP.T
Shareholders and the investment community became concerned that Medexus Pharmaceuticals (MDP.T) would not be able to deal with the imminent expiry of convertible debentures the company had issued early…
Specialty pharmaceuticals is a unique niche in the pharma sector. Where companies like Eli Lilly pour billions into developing a drug candidate from scratch with the very real possibility…
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story Specialty pharmaceuticals is a unique niche in the pharma sector. Where companies like Eli Lilly pour billions into developing…
Buzz on the discussion boards when it comes to Medexus and a series of debentures expiring next year, has not been positive, but is there any basis for real…
Specialty pharma company, Medexus Pharmaceuticals (MDP.TO) released fiscal Q3 2023 (quarter ended December 31st 2022) operating and financial results. The company has announced another record quarter with revenue of…
On February 8th, Medexus Pharmaceuticals, a Canadian-based specialty pharma company, will release its quarterly financials. Why is this a big deal? Well, the company, serving both Canada and the…
*originally published January 24, 2023 Medexus Pharmaceuticals (MDP.T) is a Canadian specialty pharma company servicing the North American market. The company has developed a robust portfolio of orphan drugs…
*originally published January 26, 2023 Medexus Pharmaceuticals (MDP.T) is a Canadian specialty pharma company on a mission to help humanity by bringing previously approved orphan drugs in other jurisdictions…